NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Harwood Feffer
LLP (www.hfesq.com) is investigating potential claims against the
board of directors of PharMerica Corporation ("PharMerica" or the
"Company") (NYSE: PMC) concerning the proposed sale of the Company
to KKR & Co. ("KKR") and Walgreens Boots Alliance Inc.
("Walgreens").
Under the terms of the agreement, KKR and Walgreens would
acquire PharMerica in a transaction valued at approximately
$1.4 billion. Pursuant to the deal,
PharMerica stockholders will receive $29.25 in cash per share. At least one analyst
had a price target of $31.00 per
share.
Our investigation concerns whether the PharMerica board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company stockholders.
If you own PharMerica shares and wish to discuss this matter
with us, or have any questions concerning your rights and interests
with regard to this matter, please contact:
Daniella Quitt, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212) 935-7400
Email: dquitt@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-proposed-sale-of-pharmerica-corporation-300498471.html
SOURCE Harwood Feffer LLP